all report title image
  • Published On : Nov 2022
  • Code : CMI1944
  • Industry : Medical Devices
  • Pages : 156
  • Formats :

Nasal drug delivery system is an alternative to invasive administrations and provides direct access to systemic circulation. Intranasal drug delivery is common and most preferred route of administration in treatment of allergic and non-allergic rhinitis, pain, acute treatment of migraine, and nasal congestion associated with sinusitis, common cold or rhinitis. Nasal drug delivery systems are mostly used in case wherein rapid onset of action is required, or to reach the site where other routes of administration display ineffective results. Nasal drug delivery is also preferred route for needle-free vaccination and systemic drug delivery. Liquid nasal preparations can be administered through inhalers, droppers, spray pumps, nebulizers or atomizers.

Global nasal drug delivery systems market is estimated to be valued at US$ 60.3 million in 2022 and is expected to exhibit a CAGR of 6.3% during the forecast period (2022-2030).

Figure 1. Global Nasal Drug Delivery Systems Market Share (%), by Dosage Form, 2022

Nasal Drug Delivery Systems  | Coherent Market Insights

Increasing product approvals by regulatory authorities is expected to drive growth of the global nasal drug delivery systems market.

Increasing product approvals by regulatory authorities is expected to drive growth of the global nasal drug delivery systems market. For instance, on March 18, 2019, Aptar Pharma, a drug delivery systems provider, had announced that the company’s product Bidose nasal spray device had received approval from the U.S. Food and Drug administration (FDA) for a breakthrough therapy in the field of depression.

CMI table icon

Nasal Drug Delivery Systems Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 60.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 6.3% 2030 Value Projection: US$ 98.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Dosage Form: Nasal Spray, Nasal Drops, Nasal Gels, Nasal Powders, Others
  • By Container Type: Non-pressurized Containers, Pressurized Containers
  • By System Type: Multi Dose, Bi Dose, Unit Dose
  • By Therapeutics Application: Allergic and Non-allergic Rhinitis, Nasal Congestion, Vaccination, Others
  • By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG

Growth Drivers:
  • Increasing product approvals by regulatory authorities
  • Increasing product launches by market players 
Restraints & Challenges:
  • Limitations associated with nasal drug delivery systems

Figure 2.Global Nasal Drug Delivery Systems Market Share (%), by Region, 2022

Nasal Drug Delivery Systems  | Coherent Market Insights

Increasing product launches by market players is expected to drive the global nasal drug delivery systems market growth.

Increasing product launches by market players is expected to drive the market growth over the forecast period. For instance, on December 22, 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.), announced the launch of generic version of Narcan1 (naloxone hydrochloride nasal spray). Moreover, naloxone hydrochloride nasal spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems or inability to respond.

Global Nasal Drug Delivery Systems Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 pandemic had a positive impact on the global nasal drug delivery systems market, owing to increased product launches by market players for protecting  patients from coronavirus infection. For instance, on February 09, 2022, Glenmark Pharmaceuticals Limited, a global pharmaceutical company and Canada based pharmaceutical company SaNOtize Research & Development Corp., announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India for the treatment of adult patients with COVID-19 who have high risk of progression of the disease.

Global Nasal Drug Delivery Systems Market: Key Developments

On April 28, 2022, Birmingham Biotech, a company that offers a wide variety of in vitro diagnostic solutions, medical devices and equipment, announced the Singapore launch of its latest technology the BHM Anti-Viral Nasal Spray, an easy-to-use nasal device with a unique patented formulation, Norizite, designed to help prevent infection from the inhalation of airborne viruses within the nasal passages.

Global Nasal Drug Delivery Systems Market: Restraint

Limitations associated with nasal drug delivery system such as histological toxicity or lesser area of absorption as compared to orally administered drug hinders the nasal drug delivery systems market growth.

Key Players

Major players operating in the global nasal drug delivery systems market include Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG.

Nasal cavity is becoming one of the most potential and promising route of drug delivery, owing to its advantages such as bypassing the hepatic first-pass metabolism, and most importantly patient convenience. The nasal drug delivery systems used in the treatment of pain, acute migraine treatment, allergic and non-allergic rhinitis, and nasal congestion brought on by sinusitis, the common cold, or rhinitis. Nasal medication delivery is typically employed when a beginning of action is desired or when other routes of administration prove unsuccessful. Systemic drug administration and needle-free immunization is possible with the help of nasal drug delivery systems. It is possible to use inhalers, droppers, spray pumps, nebulizers, or atomizers to give liquid nasal solutions.

Market Dynamics

Increasing research and development activities for nasal drug delivery systems is expected to drive growth of the global nasal drug delivery system market over the forecast period. For instance, on April 5, 2022, Upperton Pharma Solutions, a U.K. based contract development and manufacturing organization (CDMO) had launched a nasal delivery development platform, UpperNose, for small and mid-sized innovators to access the knowledge and capabilities required for the successful development of nasal dose formulations.

Furthermore, increasing product approvals by regulatory authorities is expected to drive growth of the nasal drug delivery market over the forecast period. For instance, on October 18, 2021, Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company had announced that the U.S. Food and Drug Administration (FDA) had approved TYRVAYA (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray is the first and only nasal spray approved for the treatment of dry eye disease. TYRVAYA Nasal Spray is believed to bind to cholinergic receptors to activate the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease.

Key features of the study:

  • This report provides an in-depth analysis of the global nasal drug delivery systems market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global nasal drug delivery systems market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global nasal drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal drug delivery systems market

Detailed Segmentation:

  • Global Nasal Drug Delivery Systems Market, By Dosage Form:
    • Nasal Spray
    • Nasal Drops
    • Nasal Gels
    • Nasal Powders
    • Others
  • Global Nasal Drug Delivery Systems Market, By Container Type:
    • Non-pressurized Containers
    • Pressurized Containers
  • Global Nasal Drug Delivery Systems Market, By System Type
    • Multi Dose
    • Bi Dose
    • Unit Dose
  • Global Nasal Drug Delivery Systems Market, By Therapeutics Application:
    • Allergic and Non-allergic Rhinitis
    • Nasal Congestion
    • Vaccination
    • Others
  • Global Nasal Drug Delivery Systems Market, By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Nasal Drug Delivery Systems Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Merck & Co., Inc. *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • GlaxoSmithKline plc
    • AstraZeneca plc
    • Johnson & Johnson
    • Pfizer Inc.
    • Baxter International, Inc.
    • Valeant Pharmaceuticals International, Inc.
    • Becton, Dickinson and Company
    • Novartis AG.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global nasal drug delivery systems market size is estimated to be valued at US$ 60.3 million in 2022 and is expected to exhibit a CAGR of 6.3% between 2022 and 2030.
Factors such as increasing product approvals by regulatory authorities and increasing product launches by market players are major factors driving the market growth.
Nasal Spray is the leading Dosage Form segment in the market.
The major factors hampering growth of the market include limitations associated with nasal drug delivery systems.
Major players operating in the market include Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo